Aberrant E-cadherin and α-catenin expression in prostate cancer: Correlation with patient survival

Cancer Research

Volumn 57, Issue 15, 1997, Pages 3189-3193

  Richmond, Paul J M ^a   Karayiannakis, Anastasios J ^b   Nagafuchi, Akira ^c   Kaisary, Amir V ^a   Pignatelli, Massimo ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN;

AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL MEMBRANE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REGRESSION ANALYSIS; SURVIVAL RATE;

AGED; ALPHA CATENIN; CADHERINS; CYTOSKELETAL PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0030811614     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science (Washington DC), 257: 1451-1455, 1991
2. Hinck, L., Näthke, I. S., Papkoff, J., and Nelson, W. J. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J. Cell Biol., 125: 1327-1340, 1994.
3. Hirano, S., Kimoto, N., Shimoyama, Y., Hirohashi, S., and Takeichi, M. Identification of a neural α-catenin as a key regulator of cadherin function and multicellular organization. Cell, 70: 293-301, 1992.
4. Shimoyama, Y., Nagafuchi, A., Fujita, S., Gotoh, M., Takeichi, M., Tsukita, S., and Hirohashi, S. Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res., 52: 5770-5774, 1992.
5. Behrens, J., Mareel, M. M., Van Roy, F. M., and Birchmeier, W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol., 108: 2435-2447, 1989.
6. Vleminckx, K., Vakaet, L., Jr., Mareel, M., Hers, W., and Van Roy, F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 66: 107-119, 1991.
7. Bussemakers, M. J. G., Van Moorselaar, R. J. A., Giroldi, L. A., Ichikawa, T., Isaacs, J. T., Takeichi, M., Debruyne, F. M. J., and Schalken, J. A. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res., 52: 2916-2922, 1992.
8. Siitonen, S. M.; Kononen, J. T., Helin, H. J., Rantala, I. S., Holli, K. A., and Isola, J. J. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am. J. Clin. Pathol, 105: 394-402, 1996.
9. Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W., and Funke, I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res., 53: 1690-1695, 1993.
10. Syrigos, K. N., Krausz, T., Waxman, J., Pandha, H., Rowlinson-Busza, G., Verne, J., Epenetos, A. A., and Pignatelli, M. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int. J. Cancer, 64: 367-370, 1995.
11. Pignatelli, M., Ansari, T. W., Gunter, P., Liu, D., Hirano, S., Takeichi, M., Klöppel, G., and Lemoine, N. R. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J. Pathol., 174: 243-248, 1994.
12. Dorudi, S., Sheffield, J. P., Poulsom, R., Northover, J. M. A., and Hart, I. R. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am. J. Pathol., 142: 981-986, 1993.
13. Kadowaki, T., Shiozaki, H., Inoue, M., Tamura, S., Oka, H., Doki, Y., Iihara, K., Matsui, S., Iwazawa, T., Nagafuchi, A., Tsukita, S., and Mon, T. E-cadherin and α-catenin expression in human esophageal cancer. Cancer Res., 54: 291-296, 1994.
14. Matsui, S., Shiozaki, H., Inoue, M., Tamura, S., Doki, Y., Kadowaki, T., Iwazawa, T., Shimaya, K., Nagafuchi, A., Tsukita, S., and Mori, T. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch. A., 424: 375-381, 1994.
15. Rimm, D. L., Sinard, J. H., and Morrow, J. S. Reduced α-catenin and E-cadherin expression in breast cancer. Lab. Invest., 72: 506-512, 1995.
16. Shimazui, T., Schalken, J. A., Giroldi, L. A., Jansen, C. F. J., Akaza, H., Koiso, K., Debruyne, F. M. J., and Bringuier, P. P. Prognostic value of cadherin-associated molecules (α-, β-, and γ-catenins and p120cas) in bladder tumors. Cancer Res., 56: 4154-4158, 1996.
17. Otto, T., Rembrink, K., Goepel, M., Meyer-Schwickerath, M., and Rubben, H. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol. Res., 21: 359-362, 1993.
18. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. E., Debruyne, F. M. J., and Isaacs, W. B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer Cancer Res., 52: 5104-5109, 1992.
19. Cheng, L., Nagabhushan, M., Pretlow, T. P., Amini, S. B., and Pretlow, T. G. Expression of E-cadherin in primary and metastalic prostate cancer. Am. J. Pathol 148: 1375-1380, 1996.
20. Umbas, R., Isaacs, W. B., Bringuier, P. P., Schaafsma, H. E., Karthaus, H. F. M., Oosterhof, G. O. N., Debruyne, F. M. J., and Schalken, J. A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54: 3929-3933, 1994.
21. Ross, J. S., Figge, H. L., Bui, H. X., del Rosario, A. D., Fisher, H. A., Nazeer, T., Jennings, T. A., Ingle, R., and Kim, D. N. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod. Pathol., 7: 835-841, 1994.
22. Morton, R. A., Ewing, C. M., Nagafuchi, A., Tsukita, S., and Isaacs, W. B. Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res., 53: 3585-3590, 1993.
23. Humphrey, P., and Vollmer, R. T. The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis. Hum. Pathol., 19: 411-418, 1988.
24. Gleason, D. F. Histologic grading and clinical staging of prostatic carcinoma. In: M. Tannenbaum (ed.), Urologic Pathology: The Prostate, pp. 171-197. Philadelphia: Lea & Febiger, 1977.
25. Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S., and Moinuddin, M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer (Phila.), 61: 195-202, 1988.
26. Jankowski, J. A., Newham, P. M., Kandemir, O., Hirano, S., Takeichi, M., and Pignatelli, M. Differential expression of E-cadherin in normal, metaplastic and dysplastic oesophageal mucosa: a putative biomarker. Int. J. Oncol., 4: 441-448, 1994.
27. Jawhari, A., Jordan, S., Poole, S., Browne, P., Pignatelli, M., and Farthing, M. J. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology, 112: 46-54, 1997.
28. Nagafuchi, A., Takeichi, M., and Tsukita, S. The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell, 65: 849-857, 1991.
29. Isaacs, W. B., Bova, G. S., Morton, R. A., Bussemakers, M. J., Brooks, J. D., and Ewing, C. M. Molecular biology of prostate cancer progression. Cancer Surv., 23: 19-32, 1995.